Levilimab clinical trials
Also written BCD-089.
How each study uses levilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses levilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid ArthritisActive, not recruitingPhase 3BiocadNCT05800327Written as Levilimab
- Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisCompletedPhase 3BiocadNCT04227366Written as BCD-089
- A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19CompletedPhase 3BiocadNCT04397562Written as Levilimab
- The BCD-089 (aIL6R) in Patients With Active Rheumatoid ArthritisCompletedPhase 2BiocadNCT03455842Written as BCD-089, 162 mg, s/c, qw
- First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy SubjectsCompletedPhase 1BiocadNCT03103438Written as BCD-089
Codes
What other systems call levilimab · ClinicalTrials.gg INT001462
- MeSH (NLM) C000711672levilimabOne source NLM
- UNII (FDA) P7UV3L2H80LEVILIMABConfirmed FDA, NLM
- NCI Thesaurus C173804LevilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711672 | levilimab | One source NLM |
| UNII (FDA) | P7UV3L2H80 | LEVILIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C173804 | Levilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.